[HTML][HTML] Anti-inflammatory agents: present and future
CA Dinarello - Cell, 2010 - cell.com
Inflammation involving the innate and adaptive immune systems is a normal response to
infection. However, when allowed to continue unchecked, inflammation may result in …
infection. However, when allowed to continue unchecked, inflammation may result in …
Inflammasomes in carcinogenesis and anticancer immune responses
In the complex interplay between malignant cells and their microenvironment, caspase-1
activation complexes (inflammasomes) have contrasting roles. Inflammasomes may operate …
activation complexes (inflammasomes) have contrasting roles. Inflammasomes may operate …
[HTML][HTML] Why not treat human cancer with interleukin-1 blockade?
CA Dinarello - Cancer and Metastasis Reviews, 2010 - Springer
The clinical successes of targeting angiogenesis provide a basis for trials of interleukin-1 (IL-
1) blockade and particularly anti-IL-1β as an add-on therapy in human metastatic disease. In …
1) blockade and particularly anti-IL-1β as an add-on therapy in human metastatic disease. In …
Salivary immunosuppressive cytokines IL-10 and IL-13 are significantly elevated in oral squamous cell carcinoma patients
S Aziz, SS Ahmed, A Ali, FA Khan, G Zulfiqar… - Cancer …, 2015 - Taylor & Francis
Oral squamous cell carcinoma (OSCC) is considered to be one of the most fatal diseases
worldwide, owing to its late diagnosis and lack of availability of established reliable …
worldwide, owing to its late diagnosis and lack of availability of established reliable …
IL-1 in colon inflammation, colon carcinogenesis and invasiveness of colon cancer
E Voronov, RN Apte - Cancer microenvironment, 2015 - Springer
Abstract Interleukin-1 (IL-1) is a major “alarm” upstream pro-inflammatory cytokine that
mainly acts by inducing cascades of cytokine and inflammation-promoting mediators. In the …
mainly acts by inducing cascades of cytokine and inflammation-promoting mediators. In the …
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy
E De Mattia, E Cecchin, G Toffoli - Drug Resistance Updates, 2015 - Elsevier
Colorectal cancer (CRC) represents one of the most common malignancies and is major
cause of cancer-related deaths worldwide. A great improvement in response rate and …
cause of cancer-related deaths worldwide. A great improvement in response rate and …
[HTML][HTML] Interleukins (cytokines) as biomarkers in colorectal cancer: Progression, detection, and monitoring
Cancer is the primary cause of death in economically developed countries and the second
leading cause in developing countries. Colorectal cancer (CRC) is the third most common …
leading cause in developing countries. Colorectal cancer (CRC) is the third most common …
[HTML][HTML] Colorectal cancer and NF-κB signaling pathway
P Hassanzadeh - Gastroenterology and hepatology from bed to …, 2011 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is the second leading cause of cancer death. Progress has been
made in the development of chemotherapy for advanced CRC. Targeted therapies against …
made in the development of chemotherapy for advanced CRC. Targeted therapies against …
Interleukin genes and associations with colon and rectal cancer risk and overall survival
KL Bondurant, A Lundgreen, JS Herrick… - … journal of cancer, 2013 - Wiley Online Library
Interleukins are a group of cytokines that contribute to growth and differentiation, cell
migration, and inflammatory and anti‐inflammatory responses by the immune system. In our …
migration, and inflammatory and anti‐inflammatory responses by the immune system. In our …
Targeting NF-κB for colorectal cancer
K Sakamoto, S Maeda - Expert opinion on therapeutic targets, 2010 - Taylor & Francis
Importance of the field: Colorectal cancer (CRC) is the second leading cause of cancer
death. Progress has been made in the development of chemotherapy for advanced CRC …
death. Progress has been made in the development of chemotherapy for advanced CRC …